Is Applied Therapeutics (APLT) Outperforming Other Medical Stocks This Year?
Here is how Applied Therapeutics Inc. (APLT) and Axonics Modulation Technologies (AXNX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Applied Therapeutics (APLT) This Year?
Here is how Applied Therapeutics Inc. (APLT) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year.
Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year?
Here is how Applied Therapeutics Inc. (APLT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
All You Need to Know About Applied Therapeutics (APLT) Rating Upgrade to Buy
Applied Therapeutics (APLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
APLT Stock Soars 69% on Positive Update on Galactosemia Drug NDA
Applied Therapeutics stock surges 69% as the FDA says that no advisory committee meeting is required to discuss the govorestat NDA for classic galactosemia.
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer
Applied Therapeutics, Inc.'s stock surged nearly 70% yesterday after the news that the FDA will not hold an AdCom to discuss approval of AT-007 in galactosemia. AT-007 has shown clinical benefits in galactosemia and SORD deficiency, and its PDUFA for the former arrives at the end of November. With no AdCom, approval seems the likeliest outcome. Despite financial constraints, strong patient and HCP support suggest a successful commercial launch for govorestat, making Applied stock a “Buy” with expected valuation growth.
Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review
FDA removes the need for an advisory panel to first give a recommendation review of Applied Therapeutics, Inc.'s govorestat for the treatment of patients with galactosemia. PDUFA date of November 28th, 2024, remains on track for the FDA to decide whether govorestat should be approved to treat patients with galactosemia. Pre-NDA meeting with FDA expected in 2nd half of 2024 to discuss possible administrative actions of NDA filing submission of govorestat for the treatment of patients with SORD deficiency.
Why Applied Therapeutics Stock Is Skyrocketing Today
The FDA won't hold an Advisory Committee meeting to review Applied Therapeutics' regulatory filing for govorestat. This move could increase the likelihood that the drug will win FDA approval.
Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside
William Blair initiated coverage on Applied Therapeutics Inc. APLT, a late-stage development company focused on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy.
Top 4 Health Care Stocks That May Keep You Up At Night This Month
As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Applied Therapeutics: A Strong Buy With AT-007 Nearing Approval For Galactosemia
Applied Therapeutics is a clinical-stage biotech focused on treating symptoms of galactosemia in the central nervous system. Govorestat (AT-007) is in late-stage regulatory approval for galactosemia, with a PDUFA date set for November 2024. APLT holds $146.5 million in cash, ensuring a sufficient runway to FDA approval and initial product revenues by early 2025.
